711 related articles for article (PubMed ID: 18381756)
1. Intensive induction chemotherapy followed by high dose chemotherapy with autologous hematopoietic progenitor cell rescue in young children newly diagnosed with central nervous system atypical teratoid rhabdoid tumors.
Gardner SL; Asgharzadeh S; Green A; Horn B; McCowage G; Finlay J
Pediatr Blood Cancer; 2008 Aug; 51(2):235-40. PubMed ID: 18381756
[TBL] [Abstract][Full Text] [Related]
2. Intensive induction chemotherapy followed by myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for young children newly-diagnosed with central nervous system atypical teratoid/rhabdoid tumors: the Head Start III experience.
Zaky W; Dhall G; Ji L; Haley K; Allen J; Atlas M; Bertolone S; Cornelius A; Gardner S; Patel R; Pradhan K; Shen V; Thompson S; Torkildson J; Sposto R; Finlay JL
Pediatr Blood Cancer; 2014 Jan; 61(1):95-101. PubMed ID: 23934933
[TBL] [Abstract][Full Text] [Related]
3. Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): report of the Head Start I and II experience.
Fangusaro J; Finlay J; Sposto R; Ji L; Saly M; Zacharoulis S; Asgharzadeh S; Abromowitch M; Olshefski R; Halpern S; Dubowy R; Comito M; Diez B; Kellie S; Hukin J; Rosenblum M; Dunkel I; Miller DC; Allen J; Gardner S
Pediatr Blood Cancer; 2008 Feb; 50(2):312-8. PubMed ID: 17668858
[TBL] [Abstract][Full Text] [Related]
4. Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue.
Zacharoulis S; Levy A; Chi SN; Gardner S; Rosenblum M; Miller DC; Dunkel I; Diez B; Sposto R; Ji L; Asgharzadeh S; Hukin J; Belasco J; Dubowy R; Kellie S; Termuhlen A; Finlay J
Pediatr Blood Cancer; 2007 Jul; 49(1):34-40. PubMed ID: 16874765
[TBL] [Abstract][Full Text] [Related]
5. Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue.
Thorarinsdottir HK; Rood B; Kamani N; Lafond D; Perez-Albuerne E; Loechelt B; Packer RJ; MacDonald TJ
Pediatr Blood Cancer; 2007 Mar; 48(3):278-84. PubMed ID: 16456857
[TBL] [Abstract][Full Text] [Related]
6. Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry.
Hilden JM; Meerbaum S; Burger P; Finlay J; Janss A; Scheithauer BW; Walter AW; Rorke LB; Biegel JA
J Clin Oncol; 2004 Jul; 22(14):2877-84. PubMed ID: 15254056
[TBL] [Abstract][Full Text] [Related]
7. Outcome of patients with recurrent medulloblastoma or central nervous system germinoma treated with low dose continuous intravenous etoposide along with dose-intensive chemotherapy followed by autologous hematopoietic stem cell rescue.
Grodman H; Wolfe L; Kretschmar C
Pediatr Blood Cancer; 2009 Jul; 53(1):33-6. PubMed ID: 19326417
[TBL] [Abstract][Full Text] [Related]
8. Intensive multimodality therapy for patients with stage 4a metastatic retinoblastoma.
Dunkel IJ; Khakoo Y; Kernan NA; Gershon T; Gilheeney S; Lyden DC; Wolden SL; Orjuela M; Gardner SL; Abramson DH
Pediatr Blood Cancer; 2010 Jul; 55(1):55-9. PubMed ID: 20486171
[TBL] [Abstract][Full Text] [Related]
9. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue.
Freilich RJ; Kraus DH; Budnick AS; Bayer LA; Finlay JL
Med Pediatr Oncol; 1996 Feb; 26(2):95-100. PubMed ID: 8531860
[TBL] [Abstract][Full Text] [Related]
10. High-dose chemotherapy with autologous hematopoietic stem cell rescue for stage 4B retinoblastoma.
Dunkel IJ; Chan HS; Jubran R; Chantada GL; Goldman S; Chintagumpala M; Khakoo Y; Abramson DH
Pediatr Blood Cancer; 2010 Jul; 55(1):149-52. PubMed ID: 20486181
[TBL] [Abstract][Full Text] [Related]
11. Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy.
Tekautz TM; Fuller CE; Blaney S; Fouladi M; Broniscer A; Merchant TE; Krasin M; Dalton J; Hale G; Kun LE; Wallace D; Gilbertson RJ; Gajjar A
J Clin Oncol; 2005 Mar; 23(7):1491-9. PubMed ID: 15735125
[TBL] [Abstract][Full Text] [Related]
12. Atypical teratoid or rhabdoid tumors: improved outcome with high-dose chemotherapy.
Finkelstein-Shechter T; Gassas A; Mabbott D; Huang A; Bartels U; Tabori U; Janzen L; Hawkins C; Taylor M; Bouffet E
J Pediatr Hematol Oncol; 2010 Jul; 32(5):e182-6. PubMed ID: 20495479
[TBL] [Abstract][Full Text] [Related]
13. High-dose chemotherapy and autologous hematopoietic progenitor cell rescue in children with recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors: the impact of prior radiotherapy on outcome.
Butturini AM; Jacob M; Aguajo J; Vander-Walde NA; Villablanca J; Jubran R; Erdreich-Epstein A; Marachelian A; Dhall G; Finlay JL
Cancer; 2009 Jul; 115(13):2956-63. PubMed ID: 19402050
[TBL] [Abstract][Full Text] [Related]
14. No salvage using high-dose chemotherapy plus/minus reirradiation for relapsing previously irradiated medulloblastoma.
Massimino M; Gandola L; Spreafico F; Biassoni V; Luksch R; Collini P; Solero CN; Simonetti F; Pignoli E; Cefalo G; Poggi G; Modena P; Mariani L; Potepan P; Podda M; Casanova M; Pecori E; Acerno S; Ferrari A; Terenziani M; Meazza C; Polastri D; Ravagnani F; Fossati-Bellani F
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1358-63. PubMed ID: 19019566
[TBL] [Abstract][Full Text] [Related]
15. High-dose thiotepa and etoposide-based regimens with autologous hematopoietic support for high-risk or recurrent CNS tumors in children and adults.
Papadopoulos KP; Garvin JH; Fetell M; Vahdat LT; Garrett TJ; Savage DG; Balmaceda C; Bruce J; Sisti M; Isaacson S; De LaPaz R; Hawks R; Bagiella E; Antman KH; Hesdorffer CS
Bone Marrow Transplant; 1998 Oct; 22(7):661-7. PubMed ID: 9818693
[TBL] [Abstract][Full Text] [Related]
16. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Abrey LE; Moskowitz CH; Mason WP; Crump M; Stewart D; Forsyth P; Paleologos N; Correa DD; Anderson ND; Caron D; Zelenetz A; Nimer SD; DeAngelis LM
J Clin Oncol; 2003 Nov; 21(22):4151-6. PubMed ID: 14615443
[TBL] [Abstract][Full Text] [Related]
17. Continuous remission of newly diagnosed and relapsed central nervous system atypical teratoid/rhabdoid tumor.
Zimmerman MA; Goumnerova LC; Proctor M; Scott RM; Marcus K; Pomeroy SL; Turner CD; Chi SN; Chordas C; Kieran MW
J Neurooncol; 2005 Mar; 72(1):77-84. PubMed ID: 15803379
[TBL] [Abstract][Full Text] [Related]
18. Brainstem primitive neuroectodermal tumors (bstPNET): results of treatment with intensive induction chemotherapy followed by consolidative chemotherapy with autologous hematopoietic cell rescue.
Fangusaro JR; Jubran RF; Allen J; Gardner S; Dunkel IJ; Rosenblum M; Atlas MP; Gonzalez-Gomez I; Miller D; Finlay JL
Pediatr Blood Cancer; 2008 Mar; 50(3):715-7. PubMed ID: 17009232
[TBL] [Abstract][Full Text] [Related]
19. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
Illerhaus G; Marks R; Ihorst G; Guttenberger R; Ostertag C; Derigs G; Frickhofen N; Feuerhake F; Volk B; Finke J
J Clin Oncol; 2006 Aug; 24(24):3865-70. PubMed ID: 16864853
[TBL] [Abstract][Full Text] [Related]
20. Supratentorial primitive neuroectodermal tumors (S-PNET) in children: A prospective experience with adjuvant intensive chemotherapy and hyperfractionated accelerated radiotherapy.
Massimino M; Gandola L; Spreafico F; Luksch R; Collini P; Giangaspero F; Simonetti F; Casanova M; Cefalo G; Pignoli E; Ferrari A; Terenziani M; Podda M; Meazza C; Polastri D; Poggi G; Ravagnani F; Fossati-Bellani F
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1031-7. PubMed ID: 16343801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
